Strawberry breeder accuses competitor of patent infringement
A California-based company which breeds berries has filed a patent infringement claim against a competitor.
CJEU puts further breaks on SPCs
The Court of Justice of the European Union yesterday, March 21, handed down a supplementary protection certificate decision referred to it by the English High Court.
Seven new drugs to join $1bn club by 2021, says Clarivate
Seven new drugs are forecasted to achieve annual sales of $1 billion or more by 2023, according to a new report.
WHO to begin working on gene editing research registry
World Health Organization (WHO) experts have called for central registry on human genome editing research is needed, among a committee consensus that it would be irresponsible for any scientist to conduct gene-editing studies in people.
EU court backs medical device company over EUIPO
The EU General Court yesterday, March 20, annulled a European Union Intellectual Property Office (EUIPO) decision and handed a trademark victory to Spain-based Prim.
Allergan and tribe hit back at Mylan claims in SCOTUS brief
Allergan and the Saint Regis Mohawk Tribe have again urged the US Supreme Court to hear their closely-followed litigation on tribal sovereign immunity, following a submission from generic maker Mylan in the case.
SCOTUS to hear pharmaceutical patent dispute
The US Supreme Court will seek the advice of the country’s solicitor general after it agreed to hear an appeal in a dispute over whether a medical treatment is directed towards a natural law.
Teva enters settlement with Novo Nordisk to sell Victoza generic
Danish pharmaceutical company Novo Nordisk and generics maker Teva have reached a settlement in their US dispute over Victoza.
Federal Circuit rules ‘treatment claims’ are patent eligible
The US Court of Appeals for the Federal Circuit has warned against implementing “too broad” an interpretation of the Alice test as it ruled that “treatment claims” were eligible for patenting.
Federal Circuit sends Allergan’s patent dispute back to district court
A district court must revisit its decision that one of Allergan’s patents is valid and was not infringed by a competitor.
